From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tissue Regenix – argues valuation “bears no resemblance to the prospects or the typical valuation”, but the other ‘strategic review’ participants don’t seem to concur…

By Steve Moore | Tuesday 8 April 2025


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


‘Regenerative medical devices’ group Tissue Regenix (TRX) has issued a “Conclusion of Strategic Review & Offer Period”-titled announcement including that “the board believes the company's valuation is now at a level which bears no resemblance to the prospects or the typical valuation that a business in this sector would be ascribed”. So a value-creating conclusion to the strategic review and offer period then?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

BOOM

Evil’s Rule: Audioboom

 

URU…Who R U Kidding?

Sunday »

EZJ

BUY Easyjet

Time left: 17:03:02